RDW Shows Promise as Cost-Effective Biomarker for COVID-19 Severity and Mortality

A simple blood test parameter that measures the variation in red blood cell size could help doctors identify which COVID-19 patients are most likely to die or develop severe illness. That's the finding of a review published in Biomarkers in Medicine, which examined how red blood cell distribution width—known as RDW—might serve as an early warning system during viral outbreaks when healthcare resources are stretched thin and decisions about who gets intensive care matter enormously.

RDW is not new. It's a routine measurement that appears on standard complete blood count tests, the kind of lab work doctors order constantly. What's novel is the recognition that this humble number—which reflects how much variation exists in the size of a patient's red blood cells—correlates with how sick someone will become from COVID-19. The review found that in several studies, RDW was the only routine blood parameter that independently predicted mortality. In one Spanish study of intensive care patients, an RDW reading of 13.5% identified patients at risk of dying within 30 days with 80% sensitivity, meaning it caught most of the people who would actually die. A slightly higher threshold of 14.5% was more specific, correctly identifying 81% of those who would survive.

What makes this finding potentially transformative is the economics. RDW requires no special equipment, no expensive reagents, no hours of processing. It's already measured in hospitals and clinics everywhere, even in places where resources are scarce. For developing countries managing COVID-19 without the infrastructure of wealthy nations, a biomarker that's already available and costs almost nothing to obtain could reshape how doctors triage patients and allocate limited beds and ventilators. The review's authors argue that if RDW can be standardized and refined, it could help prevent deaths by enabling early intervention in people likely to deteriorate.

But the promise comes with real complications. The same review that highlights RDW's potential also catalogs why it hasn't yet become a standard tool. Different studies report different sensitivity and specificity numbers, suggesting that how RDW is measured or interpreted varies across hospitals and countries. There is no universal reference range—what counts as abnormal in one lab might be normal in another. More fundamentally, RDW is affected by many conditions unrelated to COVID-19: anemia, thyroid problems, malnutrition, vitamin deficiencies. Age itself raises RDW, which means an older patient's elevated reading might reflect decades of life rather than current viral infection. These confounding factors reduce RDW's specificity, making it harder to know whether a high reading means COVID-19 severity or something else entirely.

The review also notes that RDW shows promise for other viral infections. Studies have found elevated RDW in patients with chronic hepatitis B, and in some cases RDW could distinguish between active and inactive hepatitis B-related cirrhosis. The pattern suggests RDW might be a general marker of how the body responds to viral stress, not a COVID-specific indicator.

What happens next depends on whether the medical community can solve the standardization problem. Researchers need to establish agreed-upon reference ranges, consistent measurement protocols, and ways to account for age and other confounding factors. The authors of the review are explicit: without this work, RDW will remain a promising curiosity rather than a clinical tool. But if those obstacles can be cleared, they argue, RDW could fundamentally change how doctors predict and manage severe viral disease, particularly in parts of the world where every resource counts.